Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Breast Cancer: early-phase trial registry
423 of 1,251 indexed Breast Cancer trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #1 of 28,963 conditions by registered trial count.
1,251 US clinical trials · 423 currently recruiting · #1 of 28,963 conditions by registered trial count
Breast Cancer: 1,251 US clinical trials tracked, 423 recruiting.
Breast Cancer is the subject of 1,251 registered US clinical trials on ClinicalTrials.gov, 423 of them currently open to new participants. 120 are in Phase 3-4 (later-stage) and 491 in Phase 1-2 (earlier-stage). The most active sponsor is Memorial Sloan Kettering Cancer Center, running 98 of these trials.
Open enrollment, early-phase tilt
Breast Cancer has 1,251 registered US clinical trials, 423 of them open to new participants right now, about 34% of the total.
- 423
- recruiting participants now
- 34%
- of trials open to enrollment
- 120
- in Phase 3-4 (later-stage)
- 98
- top sponsor: Memorial Sloan Kettering Cancer Center
Corpus placement: #1 of 28,963 conditions by registered trial count on ClinicalTrials.gov-derived indexes. Registry reference only, not medical advice.
Key findings
What ClinicalTrials.gov does not surface for Breast Cancer on its own pages , computed from the registry mirror as of 2026-07-11. Each line carries its own denominator so it can be quoted as it stands.
-
Breast Cancer is recruiting below its size-band peers.
423 of 1,251 indexed trials (33.8%) are open to enrollment, against a 37.2% average across 135 conditions with 100+ trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Breast Cancer trials is spread across many organizations.
Memorial Sloan Kettering Cancer Center accounts for 98 of 1,251 trials (7.8%). 367 distinct sponsors appear on at least one study for this condition label.
-
Typical Breast Cancer enrolment sits around 90 participants.
Median target enrolment is 90 among the 1,225 trials that report a genuine target (sentinel values excluded). 630 of those (51.4%) plan for fewer than 100 participants.
-
Breast Cancer research is mostly interventional.
1,015 interventional and 236 observational studies make up this index (81.1% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
1,251 total, page 23 of 26
IORT (Intra-operative Radiation Therapy) in Early Stage Breast Cancer
Shayna Showalter, MD
NCT01988870
The Role of Serotonin in Hot Flashes After Breast Cancer
Indiana University School of Medicine
NCT00228943
Ritonavir and Its Effects on Biomarkers in Women Undergoing Surgery for Newly Diagnosed Breast Cancer
Masonic Cancer Center, University of Minnesota
NCT01009437
Acupuncture to Reduce Chemotherapy-induced Peripheral Neuropathy Severity During Neoadjuvant or Adjuvant Weekly Paclitaxel Chemotherapy in Breast Cancer Patients
Memorial Sloan Kettering Cancer Center
NCT02364726
Evaluation of Blood/Imaging Based Biomarkers, Aromatase Inhibitor Induced Musculoskeletal Syndrome
University of Arizona
NCT03665077
Bioequivalency Study of Letrozole 2.5 mg Tablets Under Fasted Conditions
Roxane Laboratories
NCT01367652
Setup Variation in the Supraclavicular Lymph Nodes Treatment in Breast Cancer Patients
M.D. Anderson Cancer Center
NCT00658281
Open Label Trial for Post-Menopausal Women With Newly Diagnosed Operable Breast Cancer
University of Alabama at Birmingham
NCT00161291
Phase II Neoadjuvant Trial of Trastuzumab in Combination With Dose-Dense ABI-007 (Abraxane™)
Emory University
NCT00503750
An Observational Pilot Study to Test a Smartwatch-based EMA Method During Exercise With Breast Cancer Survivors
Dartmouth-Hitchcock Medical Center
NCT05868746
Exercise Intervention in Breast Cancer Patients With Treatment-Induced Arthralgia
Roswell Park Cancer Institute
NCT01236417
UFPTI 2105-BR05: Improving Breast Radiotherapy Setup and Delivery Using Mixed-Reality Visualization
University of Florida
NCT05178927
Effect of Tamoxifen or an Aromatase Inhibitor on Estrogen Metabolism in Women Treated for Newly Diagnosed Breast Cancer
University of Nebraska
NCT00569543
TOPS for African American Breast Cancer Survivors
Duke University
NCT04741802
Developing Mouse Models of Breast Cancer Using Tissue Samples From Women With Breast Cancer
Vanderbilt-Ingram Cancer Center
NCT00897468
Ceramide Cream in Treating Women With Cutaneous Breast Cancer
Alliance for Clinical Trials in Oncology
NCT00008320
Vinorelbine in Treating Older Women With Stage IV Breast Cancer
Alliance for Clinical Trials in Oncology
NCT00022152
Anastrozole and Letrozole
UConn Health
NCT00762294
Evaluation of Tumor Factors in Breast Cancer Treated With Docetaxel and Capecitabine
University of Michigan Rogel Cancer Center
NCT00156312
Growth Factor Levels in the Blood of Patients Undergoing Radiation Therapy for Epithelial Cancer
Vanderbilt-Ingram Cancer Center
NCT00897793
Imaging Biomarker for Early Detection of Treatment Efficacy During Breast Cancer Neoadjuvant Chemotherapy
University of Michigan Rogel Cancer Center
NCT02679586
Evaluation of Needle Core Biopsy of Axillary Sentinel Lymph Node in Breast Cancer
Loma Linda University
NCT02046057
Proof of Principle Trial to Determine if Nutritional Supplement Conjugated Linoleic Acid (CLA) Can Modulate the Lipogenic Pathway in Breast Cancer Tissue
Dartmouth-Hitchcock Medical Center
NCT00908791
Biological and Clinical Effects of Palbociclib With Ovarian Suppression and Letrozole in the Neoadjuvant Treatment of Breast Cancer
NSABP Foundation
NCT03628066
Docetaxel and PTK787 in Metastatic Breast Cancer Patients and Gynecological Cancer Patients
Dana-Farber Cancer Institute
NCT00268918
Vaccine Therapy, Interleukin-2, and Sargramostim in Treating Patients With Advanced Tumors
Georgetown University
NCT00003125
Novel Capecitabine Dosing Schedule in Combination With Lapatinib, Based on the Norton-Simon Mathematical Method in Patients With HER2 Overexpressed/Amplified, Trastuzumab (Herceptin) -Refractory, Metastatic Breast Cancer
Memorial Sloan Kettering Cancer Center
NCT00721630
Open-Label Study Evaluating the Safety and Tolerability of LJM716, BYL719 and Trastuzumab in Patients With Metastatic HER2+ Breast Cancer
Memorial Sloan Kettering Cancer Center
NCT02167854
Clinical Trial of Metastasis Inhibitor NP-G2-044 in Patients With Advanced or Metastatic Treatment-Refractory Solid Tumor Malignancies
Novita Pharmaceuticals
NCT03199586
Lapatinib and Doxorubicin Hydrochloride Liposome in Treating Patients With Metastatic Breast Cancer
Northwestern University
NCT00316875
A Randomized Controlled Trial To Evaluate The Use Of Botox In Breast Reconstruction With Tissue Expanders
University of Colorado, Denver
NCT01765309
Study Of MK-0752 In Combination With Tamoxifen Or Letrozole to Treat Early Stage Breast Cancer
Loyola University
NCT00756717
Nicotinic Treatment of Post-Chemotherapy Subjective Cognitive Impairment: A Pilot Study
Vanderbilt University Medical Center
NCT02312934
QOL Assessment in Breast Cancer Patients With Radiation-Induced Telangiectasias Treated With the Pulsed Dye Laser
Memorial Sloan Kettering Cancer Center
NCT01803516
Where Culture Meets Genetics: Exploring Latinas Causal Attributions of Breast and Colon Cancer and Models of Disease Inheritance
National Human Genome Research Institute (NHGRI)
NCT02767986
Avoiding Low-value Treatments in Older Women With Early-stage Breast Cancer: Piloting a Patient Decision Aid
University of Michigan Rogel Cancer Center
NCT05140252
Open-label Study of STA-9090 for Patients With Metastatic Breast Cancer
Memorial Sloan Kettering Cancer Center
NCT01273896
Healthy Eating and Active Lifestyle (HEAL): Breast Cancer Program Outcomes
AdventHealth
NCT06078761
Appetite and Exercise in Breast Cancer Survivors
University of Colorado, Denver
NCT04300478
Preoperative Regional Nerve Block for Acute and Chronic Post-Operative Pain Following Mastectomy
University of Alabama at Birmingham
NCT04019834
Vitamin D in Postmenopausal Women at High Risk for Breast Cancer
Columbia University
NCT00859651
Integrative Approaches For Cancer Survivorship 2: Project 1
University of California, San Francisco
NCT02897635
Integrative Approaches for Cancer Survivorship 2: Project 2
University of California, San Francisco
NCT02897544
Liposomal Doxorubicin Before Mastectomy in Treating Women With Invasive Breast Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT00290732
Lapatinib and Radiation Therapy in Treating Patients With Locally Recurrent or Chemotherapy-Refractory Locally Advanced or Metastatic Breast Cancer
UNC Lineberger Comprehensive Cancer Center
NCT00379509
Rosuvastatin to Lower Circulating Tissue Factor Bearing Microparticles in Metastatic Breast Cancer
Beth Israel Deaconess Medical Center
NCT01299038
Docetaxel,Carboplatin,Trastuzumab and Bevacizumab for Breast Cancer and Bone Marrow Micrometastases
Case Comprehensive Cancer Center
NCT00949247
Dakin's Solution in Preventing Radiation Dermatitis in Patients With Breast Cancer Undergoing Radiation Therapy
Stanford University
NCT02203565
Investigating the Use of taVNS to Treat Insomnia in Individuals With Breast Cancer (taVNS-insomnia-BC)
University of Alabama at Birmingham
NCT06006299
Evaluation of Breast Cancer Surgical Margins Using Optical Spectroscopy
University of Wisconsin, Madison
NCT00214292
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 235 |
| Phase 2 | 256 |
| Phase 3 | 100 |
| Phase 4 | 20 |
Top Sponsors
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
What is open for Breast Cancer right now
423 recruiting of 1,251 indexed (34% open).
Phase mix: 120 late (III/IV) vs 491 early (I/II) (early-phase heavy).
Top sponsor: Memorial Sloan Kettering Cancer Center (98 trials), 9 others listed. 50 shown below, recruiting first. #1 of 28,963 conditions by registered trial count.
How open-enrollment share is computed
Open share is recruiting_count divided by trial_count for this condition label in the public registry export. Status can change between pulls; treat the figure as a snapshot of research attention, not treatment availability.
Frequently Asked Questions
How many clinical trials are there for Breast Cancer?
PlainTrial tracks 1,251 US clinical trials for Breast Cancer, of which 423 are currently recruiting participants. Data sourced from ClinicalTrials.gov.
How do I find a recruiting trial for Breast Cancer?
Use the trial list above filtered by "Recruiting" status, or visit our trial finder at /recruiting to search by condition and state. Always discuss trial participation with your healthcare provider before enrolling.
Is this data current?
Data is sourced from ClinicalTrials.gov and reflects our most recent data pull. Trial status may have changed since then. Always verify current information at ClinicalTrials.gov before making decisions about participation.
Related
Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from ClinicalTrials.gov (National Library of Medicine). Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Source: ClinicalTrials.gov (NIH/NLM) ClinicalTrials.gov AACT registry · 2026 Trial counts and statuses sourced from ClinicalTrials.gov. Sponsor counts include both industry and federal/academic sponsors.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page aggregates every registered trial for this condition, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.